Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ETCompany ParticipantsSiting Li - IR DirectorStanley Peng - ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against solid tumors and infectious diseases, announced today that the U.S. Patent and ...

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal ...

Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome ...

“These early clinical results are exactly what we’ve been hoping for and demonstrate CHS-114’s ability to remodel the tumor microenvironment ... statements. Factors that may affect future ...

“The poster presents a significant upregulation of STAT3, IRS1/2 and b-catenin in HNSCC tumors and tumor microenvironment ... factors besides those we have listed could also adversely affect ...

MIAMI--(BUSINESS WIRE ... of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets ...

MIAMI--(BUSINESS WIRE ... of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets ...